MS and Demyelinating Disorders

The vice president of US Medical Affairs in Neurology & Immunology at EMD Serono discussed the potential for the oral multiple sclerosis therapy.

African-American patients with MS on fingolimod were 50.2% more likely to remain true to their treatment regimen than those treated with injectable disease-modifying therapies.

The EMD Serono therapy’s resubmission was accepted after a 2011 CRL, with the new NDA supported by the findings of a 5-study clinical development program.

Those treated with ocrelizumab observed a 46% reduction in their risk of progressing to a wheelchair compared to those administered placebo treatments.

The FDA has expanded the indication for fingolimod to include the treatment of children and adolescents age 10 years and older with relapsing multiple sclerosis.

5 important facts from a recent double-blind, randomized phase 3 study about siponimod in SPMS.

The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).

The disease-modifying therapy showed significant improvements in 4 TSQM measures for patients with relapsing multiple sclerosis.

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.

Alterations in the gut microbiome may trigger autoimmunity against the CNS, and contribute to the development of neuropsychiatric disorders. How? A recent review offers insights.

The injection therapy now has an indication for use in either 40 mg/mL or 20 mg/mL doses, with the lower dose having been approved in June 2015.

On the challenges of treating progressive multifocal leukoencephalopathy in MS patients.

The findings reveal that taurine could be could be added to an MS therapy regimen to boost mature oligodendrocyte production, and in turn, remyelination.

Can aspirin improve exercise endurance in people with MS? How best to treat children with MOG-Ab associated disease? What factors increase MS susceptibility?

Clinically useful Insights on multiple sclerosis culled from 3 presentations at the 7th Joint ECTRIMS-ACTRIMS conference are briefly summarized here.

A study of over 80,000 patients confirmed another strong reason to prevent young people from repetitive head blows.

Seven new drugs were approved for treatment of neurological disorders, including Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis.

Adherence is a major concern for clinicians across all disciplines. Even the most effective treatment will not be successful if the patients does not adhere to the prescribed treatment strategy. Inside learn more about the problem and ways to maximize adherence.

This case serves as a reminder to consider Baclofen overdose in the differential of select patients who present with unresponsiveness and respiratory distress.

Here is a quick primer on currently available MS therapies for partners in a patient’s healthcare team and also for patients.

The pros and cons of discontinuing disease-modifying therapies in multiple sclerosis.

May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.

Research includes impact of body weight on migraine risk, effect of sleep on MS relapse, and side effects of statins in stroke survivors.

The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.

Studies also include stem cell transplantation for treatment-refractory MS and aspirin use for headache to lessen the need for rescue medication.

Research examined no evidence of disease activity and no evidence of progression with ocrelizumab as well as long-term results with mitoxantrone.